D. E. Shaw & Co., Inc. Cerus Corp Transaction History

D. E. Shaw & Co., Inc.

$114 Billion
Q1 2024

A detailed history of D. E. Shaw & Co., Inc. transactions in Cerus Corp stock. As of the latest transaction made, D. E. Shaw & Co., Inc. holds 3,294,389 shares of CERS stock, worth $5.9 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

3,294,389

Previous 2,867,711 14.88%

Holding current value

$5.9 Million

Previous $6.19 Million 0.52%

% of portfolio

0.01%

Previous 0.01%

27 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$1.66 - $2.42 $708,285 - $1.03 Million	426,678 Added 14.88%	3,294,389 $6.23 Million
Q4 2023 Feb 14, 2024	SELL	$1.25 - $2.35 $368,843 - $693,426	-295,075 Reduced 9.33%	2,867,711 $6.19 Million
Q3 2023 Nov 14, 2023	SELL	$1.5 - $3.07 $216,274 - $442,641	-144,183 Reduced 4.36%	3,162,786 $5.12 Million
Q2 2023 Aug 14, 2023	BUY	$1.79 - $2.9 $850,495 - $1.38 Million	475,137 Added 16.78%	3,306,969 $8.14 Million
Q1 2023 May 15, 2023	BUY	$2.65 - $3.81 $1.27 Million - $1.83 Million	479,868 Added 20.4%	2,831,832 $8.41 Million

Q4 2022 Feb 14, 2023	SELL	$3.38 - $4.22 $1.77 Million - $2.21 Million	-522,799 Reduced 18.19%	2,351,964 $8.58 Million
Q3 2022 Nov 14, 2022	BUY	$3.43 - $5.83 $317,902 - $540,341	92,683 Added 3.33%	2,874,763 $10.3 Million
Q2 2022 Aug 15, 2022	BUY	$4.41 - $5.69 $180,558 - $232,965	40,943 Added 1.49%	2,782,080 $14.7 Million
Q1 2022 May 16, 2022	BUY	$4.81 - $6.99 $1.42 Million - $2.07 Million	295,765 Added 12.09%	2,741,137 $15 Million
Q4 2021 Feb 14, 2022	BUY	$5.97 - $7.93 $4.7 Million - $6.24 Million	786,686 Added 47.43%	2,445,372 $16.7 Million
Q3 2021 Nov 15, 2021	BUY	$4.79 - $6.68 $2.61 Million - $3.65 Million	545,676 Added 49.03%	1,658,686 $10.1 Million
Q2 2021 Aug 16, 2021	BUY	$5.35 - $6.35 $1.84 Million - $2.18 Million	343,602 Added 44.66%	1,113,010 $6.58 Million
Q1 2021 May 17, 2021	SELL	$5.68 - $7.87 $6.58 Million - $9.12 Million	-1,158,476 Reduced 60.09%	769,408 $4.62 Million
Q4 2020 Feb 16, 2021	BUY	$5.25 - $8.56 $1.23 Million - $2.01 Million	234,611 Added 13.86%	1,927,884 $13.3 Million
Q3 2020 Nov 16, 2020	SELL	$5.78 - $7.47 $1.58 Million - $2.04 Million	-273,058 Reduced 13.89%	1,693,273 $10.6 Million
Q2 2020 Aug 14, 2020	BUY	$4.5 - $7.02 $1.34 Million - $2.09 Million	297,692 Added 17.84%	1,966,331 $13 Million
Q1 2020 May 15, 2020	SELL	$2.87 - $5.49 $3 Million - $5.74 Million	-1,045,519 Reduced 38.52%	1,668,639 $7.76 Million
Q4 2019 Feb 14, 2020	BUY	$3.84 - $4.86 $2.79 Million - $3.53 Million	727,056 Added 36.59%	2,714,158 $11.5 Million
Q3 2019 Nov 14, 2019	BUY	$4.86 - $6.05 $2.35 Million - $2.93 Million	483,602 Added 32.17%	1,987,102 $10.2 Million
Q2 2019 Aug 14, 2019	BUY	$4.51 - $6.6 $4.05 Million - $5.92 Million	896,994 Added 147.9%	1,503,500 $8.45 Million
Q1 2019 May 15, 2019	BUY	$5.16 - $6.85 $1.34 Million - $1.77 Million	258,896 Added 74.48%	606,506 $3.78 Million
Q4 2018 Feb 14, 2019	SELL	$4.89 - $7.16 $2.43 Million - $3.55 Million	-496,191 Reduced 58.8%	347,610 $1.76 Million
Q3 2018 Nov 14, 2018	SELL	$6.89 - $7.78 $1.45 Million - $1.64 Million	-211,099 Reduced 20.01%	843,801 $6.08 Million
Q2 2018 Aug 14, 2018	BUY	$5.19 - $7.25 $2.83 Million - $3.95 Million	544,903 Added 106.84%	1,054,900 $7.04 Million
Q1 2018 May 15, 2018	SELL	$3.56 - $5.74 $564,608 - $910,352	-158,598 Reduced 23.72%	509,997 $2.79 Million
Q4 2017 Feb 14, 2018	BUY	$2.76 - $3.95 $536,535 - $767,868	194,397 Added 40.99%	668,595 $2.26 Million
Q3 2017 Nov 14, 2017	BUY	$2.22 - $2.73 $1.05 Million - $1.29 Million	474,198	474,198 $1.29 Million

Others Institutions Holding CERS

# of Institutions

153

Shares Held

144M

Call Options Held

39.6K

Put Options Held

60.9K

View Full List

About CERUS CORP

Ticker CERS
Exchange NASDAQ
Sector Healthcare
Industry Medical Devices
Shares Outstandng 177,090,000
Market Cap $317M
Description
Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended fo...

More about CERS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of D. E. Shaw & Co., Inc., based on Form 13F filings with the SEC.

News

Stay updated on D. E. Shaw & Co., Inc. with notifications on news.

Account